A 2026 Cambridge study identified a urine biomarker for ADHD — but clinical availability is still years away. Here’s what to do now.

A cross-departmental study from the University of Cambridge, published in BMC Psychiatry on May 8, 2026, identified 67 urinary metabolite markers linked to seven psychiatric conditions — 21 of them specific to a single disorder. For ADHD, the marker they flagged is N,N-dimethylglycine, a compound that shows up in urine and is detectable through the kind of test any GP orders during a routine annual checkup.

Professor Sabine Bahn, who led the research, said it plainly: “A urine test is quick, non-invasive and a routine procedure in healthcare.” If clinical trials confirm these findings, a GP could screen for ADHD without a specialist referral. No behavioral battery. No clinician subjectivity. No waiting for the one psychiatrist in your area who sees adults.

That’s the version of this story that might exist in five to ten years.

The version for today: the average wait for a formal ADHD diagnosis in the US is still 12 to 24 months — and that’s if you have insurance, live near a specialist, and know the right language to use in the referral. Many adults wait longer. And the entire process, start to finish, is 100% behavioral and subjective. Two clinicians evaluating the same patient will sometimes reach different conclusions. Whether you get diagnosed can come down to whether the person you happen to see is familiar with how ADHD presents in adults, in women, in people who’ve spent decades compensating.

So. Congratulations on the future. Here’s what to do now.

---

TL;DR

The Research	The Reality
Cambridge: 67 urinary markers for psychiatric disorders, 21 disorder-specific	No urine test exists in any clinic today
N,N-dimethylglycine flagged as ADHD-specific urinary biomarker	Needs clinical trial validation before any clinical use
Prof. Bahn: could support GP-level screening if trials confirm	US/UK ADHD diagnosis wait: 12–24 months average
Non-invasive, routine procedure — no specialist required	Current diagnosis is entirely behavioral and subjective

What this means right now: Start documenting your symptoms. Build an evidence trail. Consider telehealth routes that compress the timeline to 2–4 weeks in many states.

---

What the Cambridge ADHD Urine Biomarker Study Actually Found

The team used a method called Mendelian randomization — a genetic approach that establishes causal links between metabolite levels and conditions rather than just correlations. Instead of running an intervention trial, it uses genetic variants as proxies to infer whether a compound is causally related to a diagnosis. The advantage: faster and cheaper than traditional biomarker studies, with fewer confounding factors from lifestyle or environment.

Working across ADHD, bipolar disorder, schizophrenia, depression, anorexia, autism, and anxiety, the researchers identified 67 urinary metabolites as candidate biomarkers. For anorexia, the specific marker was altered vitamin B6 (pyridoxal). For ADHD: N,N-dimethylglycine. For bipolar disorder and schizophrenia: creatine and tyrosine changes, respectively.

The published study in BMC Psychiatry covers the full methodology. The short version: this is a legitimate, peer-reviewed finding using a sound method. It’s not a fringe claim or a preliminary preprint dressed up as a breakthrough.

But Mendelian randomization findings are a starting point, not an endpoint. They identify candidates for clinical validation. The next stage is prospective trials in real patient populations — which take years, fail at significant rates, and can surface confounding variables that weren’t apparent in the genetic analysis. Until those trials happen, N,N-dimethylglycine is a promising lead, not a diagnostic tool.

The optimistic clinical timeline, if everything goes smoothly, is probably the early 2030s at the earliest for any version of this showing up in a GP’s office. That’s not pessimism — it’s how drug and diagnostic development actually works.

This matters as context. The finding is real and it matters for the long arc of how ADHD gets diagnosed. It just doesn’t solve the problem you have this year.

---

The Diagnosis Problem This Research Doesn’t Yet Solve

Here’s what the current process actually looks like for adults who suspect they have ADHD.

You bring it up with your GP. One of three things happens: they refer you to a psychiatrist who books four months out, they try to assess you themselves with whatever ADHD training they got in medical school (which varies enormously), or they don’t take it seriously because you don’t look like the textbook image of ADHD.

If you’re in the UK, the NHS adult ADHD waitlist runs 18 months to several years in many regions. In the US, the privately insured path averages 12 to 24 months from first appointment to formal diagnosis, faster in cities, considerably longer in rural areas. The underdiagnosis problem is partly a capacity problem — there aren’t enough ADHD-trained clinicians to meet demand — and partly a training problem, where clinicians who do exist often learned to diagnose in children, not adults.

The assessment itself relies entirely on behavioral evidence: rating scales, clinical interviews, childhood history, sometimes input from a partner or parent. There are no biomarkers, no imaging, no lab values. Whether you get diagnosed depends on how your symptoms present, how well you can describe them under pressure, and whether the clinician drawing your case is familiar with the full range of ADHD presentations.

Research on waiting times and diagnostic variability makes clear that this variability isn’t small. The same patient, evaluated by different clinicians, sometimes gets different answers. For adults with inattentive-predominant ADHD, late-diagnosed women, and people who’ve built years of compensatory systems that mask symptoms in clinical settings, the stakes of that variability are particularly high. Women face this problem at structurally higher rates — the masking runs deeper, the clinician familiarity runs shallower.

The Cambridge biomarker research addresses this directly, in theory: an objective test doesn’t have an opinion about whether your symptoms seem severe enough. But that test isn’t here. Which means the most useful thing you can do right now is learn to navigate the subjective process that currently exists.

---

How Do You Document ADHD Symptoms for a Diagnosis?

This is the question the waiting period should answer. Most people show up to their first evaluation without documented symptom history, which puts the entire diagnostic burden on a 45-minute appointment with someone who’s never met them. Building a record before that appointment changes the dynamic considerably.

Here’s what to document, and how:

1. Specific incidents, not feelings. “Lost my keys three times this week, was 25 minutes late to work” is more clinically useful than “I feel scattered.” Real examples with dates.

2. Work performance evidence. Missed deadlines, projects that ran long, performance reviews that mentioned attention or organization. Documentation of functional impairment is a core diagnostic criterion — clinicians need evidence that symptoms affect real-world functioning, not just that they’re subjectively unpleasant.

3. The ASRS-v1.1 screener, completed and dated. The Adult ADHD Self-Report Scale, developed with the World Health Organization, is the most widely used adult ADHD screener in clinical settings. A completed copy is documentation you can hand directly to a clinician — it’s in their language, and it signals that you’ve engaged with the process methodically.

4. Childhood pattern evidence. Old report cards, teacher comments, notes from family. The DSM requires that symptoms were present before age 12, so anything that documents earlier difficulty — even indirectly — strengthens the case.

5. A time-of-day and context map. Not “I have trouble focusing” but “I lose track during transitions between tasks, I’m fine during hyperfocus but crash after, I miss things in conversations when there’s background noise.” Specificity is what separates a documented clinical picture from a conversation that goes nowhere.

This isn’t gaming the system. It’s doing the preparation that turns a brief intake appointment into something that produces useful diagnostic information. The Duke AI detection study published earlier this year found that the signals were present in clinical data all along — many late-diagnosed adults weren’t missed because the evidence wasn’t there, but because nobody was looking for it. Your job is to make sure the evidence is visible when someone finally does look.

---

The Tools Worth Using Right Now

The symptom documentation task is exactly where digital tools earn their keep — not because apps are magic, but because a dated digital log is harder to dismiss than notes scribbled the morning before an appointment.

For Daily Logging

Bearable handles symptom ratings, mood, sleep, and medication effects in a single daily entry and exports in formats clinicians can actually use. It’s designed for chronic condition management and doesn’t require much setup time. The key is consistency over sophistication — a simple daily log kept for four weeks is worth more than an elaborate system used for three days.

For Real-Time Capture

Voice notes beat written logs for real-time capture. When something happens, record a ten-second note. You can organize weekly rather than trying to reconstruct incidents from memory at the end of the month. The AI voice capture apps with automatic transcription remove the friction of ever needing to type — you just talk, and the log builds itself.

For Time Pattern Documentation

Time blindness apps that log actual versus estimated time for tasks generate concrete data about a core ADHD symptom that’s genuinely hard to self-report accurately. If you consistently estimate 20 minutes for tasks that take 90, that pattern documented over a few weeks is real clinical information — not vague self-report, but timestamped records.

For the ASRS itself: The full 18-question ASRS-v1.1 is free to download from Harvard Medical School’s National Comorbidity Survey site. Take it more than once, a week apart. Consistent results across sittings are more clinically meaningful than a single score.

---

Telehealth Routes: The Realistic Faster Path

The telehealth ADHD space tightened considerably between 2022 and 2025. Cerebral paused ADHD stimulant prescribing in 2022 under DEA scrutiny — a separate event from, and prior to, the broader 2023–2024 enforcement wave that followed. That wave hit other providers hard: Done Health’s founder and CEO was convicted in November 2025 on charges related to a $100M Adderall distribution and healthcare fraud scheme, and several smaller providers exited the market. The providers that remained largely shifted toward more rigorous evaluation processes.

What this means practically: telehealth ADHD diagnosis is still meaningfully faster than the traditional referral path in most US states, but the single-appointment-to-prescription pipeline is mostly gone at legitimate providers. Expect a multi-step process — intake questionnaire, video evaluation with a licensed clinician, sometimes a follow-up — before a prescription is issued.

That said, 2 to 4 weeks from first contact to diagnosis is realistic at providers like Talkiatry for adults in states that permit telehealth prescribing for Schedule II controlled substances. The evaluation quality varies between providers, and the regulatory landscape varies by state.

If stimulants aren’t your path — or you’re waiting on the traditional route — Cerebral is worth knowing about, but with a clear caveat: following its 2022 pause and subsequent acquisition of Inflow, Cerebral does not prescribe controlled substances. It offers non-stimulant ADHD medication and CBT-based support only.

What to look for:

• Multi-step evaluation, not a form-to-prescription pipeline
• Licensed prescribers with explicit ADHD-adult specialization
• State licensure matching your residence — this affects what can legally be prescribed
• Reviews from adults specifically, not general mental health users

The ADHD underdiagnosis data shows that adults with inattentive-predominant presentation and women are the most likely to be dismissed or under-evaluated in brief appointments. A provider who routinely works with adult ADHD — not a general psychiatrist who encounters it occasionally — matters for the quality of the evaluation you receive.

The post-2024 telehealth environment is more rigorous than 2021–2023. That’s genuinely a feature, not a bug. Providers who are doing evaluations carefully are the ones worth using.

---

What to Do This Week

1. Take the ASRS-v1.1 screener. Free, 18 questions, clinically validated. Not a diagnosis — a documented starting point in the language clinicians use.

2. Start logging symptoms today. Not retrospectively. Starting now. Two weeks of consistent daily notes before an appointment is worth more than six months of mental record you’re trying to reconstruct.

3. Gather historical evidence. Old report cards, performance reviews, messages from people in your life who’ve noticed patterns. Anything that speaks to pre-age-12 symptom presence is particularly useful.

4. Research telehealth options in your state. The regulatory situation varies enough that this takes 20 minutes and could save 18 months of waiting.

5. Don’t wait for the urine test. Track the Cambridge research — it’s worth following. But the test isn’t coming this year, or next year. The evidence-based strategies that work for undiagnosed adults are the same ones that work after diagnosis because the executive function challenges are the same. You don’t need a piece of paper to start accommodating your brain better. But you might need one to access medication, formal workplace accommodations, or ADHD-specific therapy.

---

The Bottom Line

Cambridge’s N,N-dimethylglycine finding is one of the more credible ADHD biomarker leads in years. The method is sound, the journal is peer-reviewed, and the implications — GP-level screening, objective markers, shorter diagnostic chains — are real if clinical trials confirm the findings.

That version of the story might arrive in the 2030s.

What exists now is a 12-to-24-month waitlist, a behavioral assessment process that depends on clinician familiarity with adult ADHD presentations, and a system that misses a significant number of the people who need it most.

Document your symptoms. Build the evidence trail. Use the validated screeners. Explore telehealth if the traditional path is unavailable or measured in years. The science is moving in the right direction — faster than it was five years ago, slower than you’d want right now.

Only the actions you take this month can change your timeline this year.

---

This post reflects publicly available research and general information about ADHD diagnosis pathways. It is not medical advice. Speak with a qualified healthcare provider about your specific situation.